Real-world analysis demonstrates sustained responses with axi-cel in patients with R/R LBCL

EHA 2025

Lymphoma

Real-world effectiveness and safety of second-line axi-cel in patients with R/R LBCL

ASH 2025

Lymphoma

Real-world comparison of commercial CAR T-cell therapies demonstrates comparable outcomes between axi-cel and liso-cel in R/R LBCL

ASH 2025

Lymphoma

TRANSCEND FL: High rates of deep and durable responses and sustained survival with liso-cel in patients with R/R FL after three years of follow-up

ASH 2025

Lymphoma

Prognostic value of early MRD status in LBCL patients treated with axi-cel or liso-cel

ASH 2025

Lymphoma

French Register data confirm robust efficacy of axi-cel and liso-cel in early-relapsing LBCL

CHICAGO 2026

Lung, Respiratory and Thoracic Cancer

Jazz EMERGE 402: Final primary analysis supports real-world effectiveness of lurbinectedin in patients with previously treated ES-SCLC

Genitourinary Cancer

Enfortumab vedotin plus pembrolizumab in treatment-naïve metastatic urothelial carcinoma patients: An Austrian real-world analysis

Int J Cancer

Niedersuess-Beke D, Mayrhofer K, Krauter J, Franke J, Vais D, Pallauf M, Kiesl D, Luger F, Pfuner J, Terbuch A, Bauernhofer T, Spielgelberg J, Banner A, Aufderklamm S, Wiesinger C, Schnabel S, Gampenrieder SP, Mühlmann J, Vallet S, Weibrecht S, Stoiber F, Andalibi H, Fajkovic H, Taghizadeh H, Miechowiecki J, Taedcke R, Heintel D, Shariat SF, Pichler M, Hilbe W, Pichler R

doi: 10.1002/ijc.70203

Multiple Myeloma (MM)

Deep and Sustained Responses with Quadruplet Carfilzomib (Kyprolis^®)-Based Regimens in Patients with NDMM

Lymphoma

Real-world treatment patterns and characteristics of patients with diffuse large B-cell lymphoma (DLBCL): a retrospective analysis of US commercial and Medicare claims (2017-2024)

Leuk Lymphoma

Phillips T, Zhou Z, Gutierrez C, Shao A, Boyd M, Noshad S, Hohlbauch A, Liu N, Repetny K, Fanale M, Mitchell B, Davis EA, Gennarelli R, Burke JM

doi: 10.1080/10428194.2025.2604300

Related content

Real-world effectiveness and safety of second-line axi-cel in patients with R/R LBCL

Real-world comparison of commercial CAR T-cell therapies demonstrates comparable outcomes between axi-cel and liso-cel in R/R LBCL

TRANSCEND FL: High rates of deep and durable responses and sustained survival with liso-cel in patients with R/R FL after three years of follow-up

Prognostic value of early MRD status in LBCL patients treated with axi-cel or liso-cel

French Register data confirm robust efficacy of axi-cel and liso-cel in early-relapsing LBCL

Jazz EMERGE 402: Final primary analysis supports real-world effectiveness of lurbinectedin in patients with previously treated ES-SCLC

Enfortumab vedotin plus pembrolizumab in treatment-naïve metastatic urothelial carcinoma patients: An Austrian real-world analysis

Deep and Sustained Responses with Quadruplet Carfilzomib (Kyprolis®)-Based Regimens in Patients with NDMM

Real-world treatment patterns and characteristics of patients with diffuse large B-cell lymphoma (DLBCL): a retrospective analysis of US commercial and Medicare claims (2017-2024)

Deep and Sustained Responses with Quadruplet Carfilzomib (Kyprolis^®)-Based Regimens in Patients with NDMM